` GRI (GRI Bio Inc) vs S&P 500 Comparison - Alpha Spread

GRI
vs
S&P 500

Over the past 12 months, GRI has underperformed S&P 500, delivering a return of -97% compared to the S&P 500's +15% growth.

Stocks Performance
GRI vs S&P 500

Loading
GRI
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GRI vs S&P 500

Loading
GRI
S&P 500
Difference
www.alphaspread.com

Performance By Year
GRI vs S&P 500

Loading
GRI
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
GRI Bio Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

GRI Bio Inc
Glance View

Market Cap
1.4m USD
Industry
Pharmaceuticals

GRI Bio Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in La Jolla, California and currently employs 2 full-time employees. The company went IPO on 2021-02-10. GRI Bio, Inc. is a clinical-stage biotechnology company. The firm is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The firm's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company’s second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need.

GRI Intrinsic Value
1.24 USD
Undervaluation 66%
Intrinsic Value
Price
Back to Top